5.0397
price down icon7.53%   -0.4103
 
loading
Precedente Chiudi:
$5.45
Aprire:
$5.47
Volume 24 ore:
1.21M
Relative Volume:
0.74
Capitalizzazione di mercato:
$325.76M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-2.6665
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
-5.45%
1M Prestazione:
+2.23%
6M Prestazione:
-40.64%
1 anno Prestazione:
+227.25%
Intervallo 1D:
Value
$4.92
$5.52
Intervallo di 1 settimana:
Value
$4.92
$5.82
Portata 52W:
Value
$1.10
$10.08

Immuneering Corp Stock (IMRX) Company Profile

Name
Nome
Immuneering Corp
Name
Telefono
617-500-8080
Name
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Name
Dipendente
54
Name
Cinguettio
Name
Prossima data di guadagno
2025-08-08
Name
Ultimi documenti SEC
Name
IMRX's Discussions on Twitter

Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMRX
Immuneering Corp
5.045 351.91M 317.00K -53.47M -49.31M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.91 121.46B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
745.27 78.93B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
703.26 43.87B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.83 42.07B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
283.51 31.65B 5.36B 287.73M 924.18M 2.5229

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-31 Iniziato Leerink Partners Outperform
2024-12-13 Downgrade Morgan Stanley Equal-Weight → Underweight
2024-03-15 Downgrade Jefferies Buy → Hold
2024-03-15 Reiterato Needham Buy
2024-03-15 Downgrade TD Cowen Outperform → Market Perform
2023-12-01 Iniziato Needham Buy
2023-06-26 Ripresa Oppenheimer Outperform
2023-04-19 Aggiornamento Mizuho Neutral → Buy
2023-04-19 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-03-30 Iniziato Mizuho Neutral
2023-02-03 Downgrade Morgan Stanley Equal-Weight → Underweight
2022-07-08 Iniziato Chardan Capital Markets Buy
2022-04-01 Iniziato Oppenheimer Outperform
2022-01-07 Iniziato Piper Sandler Overweight
Mostra tutto

Immuneering Corp Borsa (IMRX) Ultime notizie

pulisher
Mar 12, 2026

Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat

Mar 12, 2026
pulisher
Mar 09, 2026

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - Yahoo Finance

Mar 09, 2026
pulisher
Mar 09, 2026

Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com

Mar 09, 2026
pulisher
Mar 07, 2026

Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch

Mar 07, 2026
pulisher
Mar 06, 2026

Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com

Mar 06, 2026
pulisher
Mar 06, 2026

Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView

Mar 06, 2026
pulisher
Mar 06, 2026

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times

Mar 06, 2026
pulisher
Mar 02, 2026

Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times

Mar 02, 2026
pulisher
Feb 28, 2026

IMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026
pulisher
Feb 28, 2026

Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 - Yahoo Finance

Feb 28, 2026
pulisher
Feb 27, 2026

IMRX Should I Buy - Intellectia AI

Feb 27, 2026
pulisher
Feb 26, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Feb 26, 2026
pulisher
Feb 23, 2026

Merger Talk: Does Immuneering Corporation outperform in volatile marketsJuly 2025 Market Mood & Reliable Volume Spike Alerts - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 21, 2026

Investment Report: Does Immuneering Corporation meet Warren Buffetts criteriaPortfolio Update Summary & AI Based Trade Execution Alerts - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 19, 2026

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times

Feb 19, 2026
pulisher
Feb 18, 2026

Immuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative

Feb 18, 2026
pulisher
Feb 01, 2026

Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat

Feb 01, 2026
pulisher
Feb 01, 2026

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 01, 2026
pulisher
Jan 29, 2026

What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru

Jan 29, 2026
pulisher
Jan 22, 2026

Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus

Jan 22, 2026
pulisher
Jan 22, 2026

Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World

Jan 22, 2026
pulisher
Jan 21, 2026

Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat

Jan 21, 2026
pulisher
Jan 21, 2026

Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia

Jan 21, 2026
pulisher
Jan 21, 2026

Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com

Jan 21, 2026
pulisher
Jan 20, 2026

Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat

Jan 20, 2026
pulisher
Jan 20, 2026

Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India

Jan 20, 2026
pulisher
Jan 20, 2026

Immuneering director Schall buys $101k in shares - Investing.com

Jan 20, 2026
pulisher
Jan 19, 2026

Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World

Jan 19, 2026
pulisher
Jan 17, 2026

Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat

Jan 17, 2026
pulisher
Jan 16, 2026

Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus

Jan 16, 2026
pulisher
Jan 16, 2026

Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey

Jan 16, 2026
pulisher
Jan 16, 2026

Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance

Jan 16, 2026
pulisher
Jan 16, 2026

Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus

Jan 16, 2026
pulisher
Jan 15, 2026

Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria

Jan 15, 2026
pulisher
Jan 15, 2026

Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com

Jan 15, 2026
pulisher
Jan 15, 2026

Looking Into Immuneering Corp's Recent Short Interest - Sahm

Jan 15, 2026
pulisher
Jan 14, 2026

Immuneering director Feinberg buys $86k in shares By Investing.com - Investing.com Nigeria

Jan 14, 2026
pulisher
Jan 14, 2026

Immuneering director Feinberg buys $86k in shares - Investing.com

Jan 14, 2026
pulisher
Jan 12, 2026

Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX - MarketBeat

Jan 12, 2026
pulisher
Jan 11, 2026

Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance

Jan 11, 2026

Immuneering Corp Azioni (IMRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$46.06
price up icon 0.41%
$28.99
price up icon 1.33%
$54.07
price up icon 1.61%
$90.20
price up icon 0.16%
$141.15
price up icon 1.23%
biotechnology ONC
$288.30
price up icon 0.99%
Capitalizzazione:     |  Volume (24 ore):